शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BAJAJHCARENSEBajaj Healthcare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 26 May, 2025 · 19:39 IST

Bajaj Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

BAJAJHCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-7.2%Reaction day
₹605.50
prior close
₹564.45
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-7.2% vs market
Pharmaceuticals peers, median of 147sector+0.1%-7.4% vs sector

On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 7.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.4
10m
+0.2
15m
-0.4
30m
-0.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-7.2-0.1-7.2+0.1-7.4
Next day
-8.5+0.2-8.8-0.0-8.5
2d
-10.0+0.6-10.7+0.8-10.9
3d
-11.0+0.9-11.9+0.3-11.3
4d
-12.1+1.0-13.1+0.0-12.1
5d
-13.0+0.7-13.8-0.6-12.5
1w
-11.0+1.8-12.8+0.0-11.0
15d
-11.8+1.7-13.5-0.8-11.0
1m
-14.1+3.1-17.2-0.6-13.5
2m
-11.9+1.7-13.6+0.6-12.5
3m
-29.0-1.0-27.9-2.9-26.1
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bajaj Healthcare Limited has submitted its financial results for the period ended March 31, 2025 to the NSE Exchange. The announcement is a routine regulatory filing indicating the company has reported its quarterly and/or annual financial performance. No specific financial figures, revenue numbers, profit details, or auditor remarks were provided in this headline alone. Shareholders and investors would need to refer to the actual results document for detailed numbers, segment performance, and management commentary.

Likely market impact

This is a procedural disclosure confirming timely submission of results and does not by itself indicate any material change in business performance. Investors should review the detailed financials to assess actual growth, margins, and outlook before drawing conclusions.